- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07290569
Estudo de Determinação da Dose de ORKA-001 em Doentes com Psoríase em Placas de Moderada a Grave (EVERLAST-B)
Um Estudo Multicêntrico, Randomizado, Duplamente Cego, Controlado por Placebo, de Determinação de Dose de ORKA-001 em Participantes com Psoríase em Placas Moderada a Grave
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a multicenter, randomized, double-blinded, placebo-controlled, dose ranging study designed to identify the optimal induction dosing regimen of ORKA-001 in approximately 160 adult participants with moderate-to-severe plaque psoriasis.
The study will evaluate the efficacy and safety of 3 induction dosing regimens of ORKA-001 compared to placebo and will include 3 maintenance regimens.
The study will consist of 4 periods:
- Screening Period of up to 6 weeks
- Induction Period of up to 28 weeks (Day 1 [Baseline] to Week 28)
- Maintenance Period of up to approximately 72 weeks (Week 28 to Week 100)
- Post-treatment Follow-up Period: Participants will have the option to enter the open-label extension (OLE) study. Participants who opt out of the OLE study and/or withdraw from the study must be followed for 48 weeks after the End of Treatment (EOT)/Early Termination (ET) visit.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Baden-Wuerrtemberg
-
Heidelberg, Baden-Wuerrtemberg, Alemanha, 69120
- Oruka Therapeutics Investigative Site
-
-
Hesse
-
Frankfurt am Main, Hesse, Alemanha, 60590
- Oruka Therapeutics Investigative Site
-
-
Lower Saxony
-
Bad Bentheim, Lower Saxony, Alemanha, 48455
- Oruka Therapeutics Investigative Site
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Alemanha, 24105
- Oruka Therapeutics Investigative Site
-
-
-
-
British Columbia
-
Surrey, British Columbia, Canadá, V3R 6A7
- Oruka Therapeutics Investigative Site
-
Surrey, British Columbia, Canadá, V3V 0C6
- Oruka Therapeutics Investigative Site
-
-
New Brunswick
-
Fredericton, New Brunswick, Canadá, E3B 1G9
- Oruka Therapeutics Investigative Site
-
-
Ontario
-
Ajax, Ontario, Canadá, L1S 7K8
- Oruka Therapeutics Investigative Site
-
Markham, Ontario, Canadá, L3P 1X3
- Oruka Therapeutics Investigative Site
-
Peterborough, Ontario, Canadá, K9J 5K2
- Oruka Therapeutics Investigative Site
-
-
Quebec
-
Montreal, Quebec, Canadá, HZX 2V1
- Oruka Therapeutics Investigative Site
-
Québec, Quebec, Canadá, G1V 4X7
- Oruka Therapeutics Investigative Site
-
-
-
-
Barcelona
-
Badalona, Barcelona, Espanha, 08916
- Oruka Therapeutics Investigative Site
-
Barcelona, Barcelona, Espanha, 08041
- Oruka Therapeutics Investigative Site
-
-
Madrid
-
Madrid, Madrid, Espanha, 28002
- Oruka Therapeutics Investigative Site
-
Madrid, Madrid, Espanha, 28046
- Oruka Therapeutics Investigative Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85032
- Oruka Therapeutics Investigative Site
-
-
Arkansas
-
North Little Rock, Arkansas, Estados Unidos, 72117
- Oruka Therapeutics Investigative Site
-
-
California
-
Los Angeles, California, Estados Unidos, 90045
- Oruka Therapeutics Investigative Site
-
Los Angeles, California, Estados Unidos, 90024
- Oruka Therapeutics Investigative Site
-
San Diego, California, Estados Unidos, 92123
- Oruka Therapeutics Investigative Site
-
-
Florida
-
Miami, Florida, Estados Unidos, 33126
- Oruka Therapeutics Investigative Site
-
-
Illinois
-
Rolling Meadows, Illinois, Estados Unidos, 60008
- Oruka Therapeutics Investigative Site
-
-
Indiana
-
Plainfield, Indiana, Estados Unidos, 46168
- Oruka Therapeutics Investigative Site
-
-
Maryland
-
Rockville, Maryland, Estados Unidos, 20850
- Oruka Therapeutics Investigative Site
-
-
New York
-
Kew Gardens, New York, Estados Unidos, 11415
- Oruka Therapeutics Investigative Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27516
- Oruka Therapeutics Investigative Site
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- Oruka Therapeutics Investigative Site
-
Mason, Ohio, Estados Unidos, 45040
- Oruka Therapeutics Investigative Site
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97201
- Oruka Therapeutics Investigative Site
-
Portland, Oregon, Estados Unidos, 97210
- Oruka Therapeutics Investigative Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Oruka Therapeutics Investigative Site
-
-
Texas
-
Frisco, Texas, Estados Unidos, 75033
- Oruka Therapeutics Investigative Site
-
Houston, Texas, Estados Unidos, 77004
- Oruka Therapeutics Investigative Site
-
Webster, Texas, Estados Unidos, 77598
- Oruka Therapeutics Investigative Site
-
-
Virginia
-
Norfolk, Virginia, Estados Unidos, 23502
- Oruka Therapeutics Investigative Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Participants ≥ 18 years of age
-
Have a diagnosis of plaque psoriasis for > 6 months
-
Have moderate-to-severe chronic plaque psoriasis defined as:
- BSA ≥ 10%, and
- PASI ≥ 12, and
- IGA score of ≥ 3 on a 5-point scale
-
Candidate for systemic therapy or phototherapy
-
Women of childbearing potential must have a negative pregnancy test.
Exclusion Criteria:
- Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis
- Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
- History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
- A known hypersensitivity to any components of the ORKA-001 drug product
- Women who are breastfeeding or plan to breastfeed during the study
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: (Induction Period - Arm 1) ORKA-001
Participants will receive 37.5 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Experimental: (Induction Period - Arm 2) ORKA-001
Participants will receive 300 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Experimental: (Induction Period - Arm 3) ORKA-001
Participants will receive 600 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Comparador de Placebo: (Induction Period - Arm 4) Placebo
Participants will receive Placebo per protocol Induction regimen. |
Placebo administered by subcutaneous (SC) injection |
|
Experimental: (Maintenance Period - Arm 1) ORKA-001
Participants will receive 300 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Experimental: (Maintenance Period - Arm 2) ORKA-001
Participants will receive 600 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Comparador de Placebo: (Maintenance Period - Arm 3) Placebo
Participants will receive Placebo per protocol Maintenance regimen, based on protocol defined response. |
Placebo administered by subcutaneous (SC) injection |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16
Prazo: Week 16
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 16
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of Participants Who Achieve an IGA = 0 (Clear) at Week 16
Prazo: Week 16
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
Proportion of Participants Achieving 90% Reduction in PASI Score at Week 16
Prazo: Week 16
|
Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 16
|
|
Proportion of Participants Who Achieve an IGA = 0 (Clear) or 1 (Almost Clear) at Week 16
Prazo: Week 16
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
Proportion of Participants Maintaining 100% Reduction in PASI Score at Week 100
Prazo: Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Proportion of Participants Maintaining an IGA = 0 (Clear) at Week 100
Prazo: Week 100
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 100
|
|
Proportion of Participants Maintaining 90% Reduction in PASI Score at Week 100
Prazo: Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Proportion of Participants Maintaining an IGA = 0 (Clear) or 1 (Almost Clear) at Week 100
Prazo: Week 100
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 100
|
|
Proportion of Participants Maintaining 75% Reduction in PASI Score at Week 100
Prazo: Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs)
Prazo: Day 1 through Week 100
|
Incidence of treatment adverse events, treatment adverse events of special interest, and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms |
Day 1 through Week 100
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- ORKA-001-114
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .